CA3029004C - Derives de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer - Google Patents

Derives de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer

Info

Publication number
CA3029004C
CA3029004C CA3029004A CA3029004A CA3029004C CA 3029004 C CA3029004 C CA 3029004C CA 3029004 A CA3029004 A CA 3029004A CA 3029004 A CA3029004 A CA 3029004A CA 3029004 C CA3029004 C CA 3029004C
Authority
CA
Canada
Prior art keywords
cancer
methyl
oxo
dihydrophthalazin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3029004A
Other languages
English (en)
Other versions
CA3029004A1 (fr
Inventor
Tsze TSANG
Csaba J. Peto
David M. Jablons
Hassan Lemjabbar-Alaoui
Original Assignee
Atlasmedx Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlasmedx Inc, University of California San Diego UCSD filed Critical Atlasmedx Inc
Priority claimed from PCT/US2017/039119 external-priority patent/WO2017223516A1/fr
Publication of CA3029004A1 publication Critical patent/CA3029004A1/fr
Application granted granted Critical
Publication of CA3029004C publication Critical patent/CA3029004C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des dérivés de phtalazine de formule (I) qui sont des inhibiteurs de PARP1, PARP2 et/ou de tubuline et donc utiles dans le traitement du cancer. L'invention concerne également des préparations pharmaceutiques contenant ces composés, ainsi que des combinaisons de ces composés avec au moins un agent thérapeutique supplémentaire.
CA3029004A 2016-06-24 2017-06-23 Derives de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer Active CA3029004C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662354449P 2016-06-24 2016-06-24
US62/354,449 2016-06-24
US201662426095P 2016-11-23 2016-11-23
US62/426,095 2016-11-23
PCT/US2017/039119 WO2017223516A1 (fr) 2016-06-24 2017-06-23 Dérivés de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer

Publications (2)

Publication Number Publication Date
CA3029004A1 CA3029004A1 (fr) 2017-12-28
CA3029004C true CA3029004C (fr) 2025-09-09

Family

ID=

Similar Documents

Publication Publication Date Title
US12145925B2 (en) Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
US8815896B2 (en) 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2018054365A1 (fr) Nouvelles imidazo[1,5-a]pyridines substituées en position 5 ou 8 en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
WO2016130501A1 (fr) Composés aza-hétéroaryle en tant qu'inhibiteurs de pi3k-gamma
US11708352B2 (en) Anti-cancer compounds
TW202340190A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途
CN110156782B (zh) 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物
KR20190125367A (ko) 아제티딘 유도체
CA3029004C (fr) Derives de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer
CN114728998A (zh) 靶向cd73和腺苷受体的磺酰胺化合物
US20230192621A1 (en) Anti-Cancer/Anti-Fibrosis Compounds
HK40002445B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
HK40002445A (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
BR112018076821B1 (pt) Compostos ou sal, hidrato ou solvato dos mesmos, seus usos, formulação farmacêutica e método in vitro de inibição de parp1 e/ou parp2 e/ou tubulina
CN111808080B (zh) 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用